Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes.
Journal
Nature reviews. Clinical oncology
ISSN: 1759-4782
Titre abrégé: Nat Rev Clin Oncol
Pays: England
ID NLM: 101500077
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
01
03
2021
pubmed:
10
4
2021
medline:
18
9
2021
entrez:
9
4
2021
Statut:
ppublish
Résumé
Immune checkpoint inhibitors have revolutionized medical oncology, although currently only a subset of patients has a response to such treatment. A compelling body of evidence indicates that anti-angiogenic therapy has the capacity to ameliorate antitumour immunity owing to the inhibition of various immunosuppressive features of angiogenesis. Hence, combinations of anti-angiogenic agents and immunotherapy are currently being tested in >90 clinical trials and 5 such combinations have been approved by the FDA in the past few years. In this Perspective, we describe how the angiogenesis-induced endothelial immune cell barrier hampers antitumour immunity and the role of endothelial cell anergy as the vascular counterpart of immune checkpoints. We review the antitumour immunity-promoting effects of anti-angiogenic agents and provide an update on the current clinical successes achieved when these agents are combined with immune checkpoint inhibitors. Finally, we propose that anti-angiogenic agents are immunotherapies - and vice versa - and discuss future research priorities.
Identifiants
pubmed: 33833434
doi: 10.1038/s41571-021-00496-y
pii: 10.1038/s41571-021-00496-y
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
527-540Informations de copyright
© 2021. Springer Nature Limited.
Références
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastaic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
doi: 10.1056/NEJMoa1003466
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
pubmed: 28889792
pmcid: 5706778
doi: 10.1056/NEJMoa1709684
Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373, 1627–1639 (2015).
pubmed: 26412456
pmcid: 5705936
doi: 10.1056/NEJMoa1507643
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
pubmed: 26406148
pmcid: 5719487
doi: 10.1056/NEJMoa1510665
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
pubmed: 26027431
pmcid: 5698905
doi: 10.1056/NEJMoa1504030
Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793–800 (2002).
pubmed: 12091876
doi: 10.1038/nm730
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
pubmed: 28187290
pmcid: 5391692
doi: 10.1016/j.cell.2017.01.017
Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275–287 (2016).
pubmed: 27079802
pmcid: 5381938
doi: 10.1038/nrc.2016.36
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. Nature 541, 321–330 (2017).
pubmed: 28102259
doi: 10.1038/nature21349
Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
pubmed: 25399552
doi: 10.1056/NEJMoa1412082
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
pubmed: 26028407
pmcid: 4681400
doi: 10.1056/NEJMoa1504627
Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
pubmed: 23724867
pmcid: 5698004
doi: 10.1056/NEJMoa1302369
O’Donnell, J. S., Teng, M. W. L. & Smyth, M. J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 16, 151–167 (2019).
pubmed: 30523282
doi: 10.1038/s41571-018-0142-8
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
pubmed: 25838373
doi: 10.1126/science.aaa8172
Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237–251 (2012).
pubmed: 22437869
pmcid: 3967236
doi: 10.1038/nrc3237
Griffioen, A. W. & Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52, 237–268 (2000).
pubmed: 10835101
Rahma, O. E. & Hodi, F. S. The intersection between tumor angiogenesis and immune suppression. Clin. Cancer Res. 25, 5449–5457 (2019).
pubmed: 30944124
doi: 10.1158/1078-0432.CCR-18-1543
Motz, G. T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11, 702–711 (2011).
pubmed: 21941296
doi: 10.1038/nri3064
Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011–1027 (2005).
pubmed: 15585754
doi: 10.1200/JCO.2005.06.081
Gabrilovich, D. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2, 1096–1103 (1996).
pubmed: 8837607
doi: 10.1038/nm1096-1096
Wada, J. et al. The contribution of vascular endothelial growth factor to the induction of regulatory T- cells in malignant effusions. Anticancer. Res. 29, 881–888 (2009).
pubmed: 19414323
Terme, M. et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73, 539–549 (2013).
pubmed: 23108136
doi: 10.1158/0008-5472.CAN-12-2325
Huang, Y. et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110, 624–631 (2007).
pubmed: 17376891
pmcid: 1924481
doi: 10.1182/blood-2007-01-065714
Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878–4886 (2003).
pubmed: 12586633
doi: 10.1182/blood-2002-07-1956
Gavalas, N. G. et al. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br. J. Cancer 107, 1869–1875 (2012).
pubmed: 23169339
pmcid: 3504940
doi: 10.1038/bjc.2012.468
Voron, T. et al. VEGF-A modulates expression of inhibitory checkpoints on CD8
pubmed: 25601652
pmcid: 4322048
doi: 10.1084/jem.20140559
Khan, K. A. & Kerbel, R. S. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat. Rev. Clin. Oncol. 15, 310–324 (2018).
pubmed: 29434333
doi: 10.1038/nrclinonc.2018.9
Griffioen, A., Damen, C., Blijham, G. & Groenewegen, G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88, 667–673 (1996).
pubmed: 8695814
doi: 10.1182/blood.V88.2.667.bloodjournal882667
Dirkx, A. E. M. et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in Vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63, 2322–2329 (2003).
pubmed: 12727857
Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H. & Groenewegen, G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 56, 1111–1117 (1996).
pubmed: 8640769
Gajewski, T. F. et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr. Opin. Immunol. 25, 268–276 (2013).
pubmed: 23579075
doi: 10.1016/j.coi.2013.02.009
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
pubmed: 23890059
doi: 10.1016/j.immuni.2013.07.012
Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782–795 (2013).
pubmed: 24138885
doi: 10.1016/j.immuni.2013.10.003
Gajewski, T. F. The next hurdle in cancer immunotherapy: overcoming the non–T-cell–inflamed tumor microenvironment. Semin. Oncol. 42, 663–671 (2015).
pubmed: 26320069
pmcid: 4555998
doi: 10.1053/j.seminoncol.2015.05.011
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003).
pubmed: 12529460
doi: 10.1056/NEJMoa020177
Galon, J. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960–1964 (2006).
pubmed: 17008531
doi: 10.1126/science.1129139
Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865–1874 (2016).
pubmed: 27084740
doi: 10.1158/1078-0432.CCR-15-1507
Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
pubmed: 25428504
pmcid: 4836193
doi: 10.1038/nature14011
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69, 4–10 (2005).
pubmed: 16301830
doi: 10.1159/000088478
Carmeliet, P. & Jain, R. K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).
pubmed: 11001068
doi: 10.1038/35025220
Chouaib, S., Noman, M. Z., Kosmatopoulos, K. & Curran, M. A. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36, 439–445 (2017).
pubmed: 27345407
doi: 10.1038/onc.2016.225
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325–340 (2018).
pubmed: 29508855
pmcid: 5921900
doi: 10.1038/nrclinonc.2018.29
Huang, Y. et al. Improving immune–vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 18, 195–203 (2018).
pubmed: 29332937
pmcid: 5922422
doi: 10.1038/nri.2017.145
Ramjiawan, R. R., Griffioen, A. W. & Duda, D. G. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis 20, 185–204 (2017).
pubmed: 28361267
pmcid: 5439974
doi: 10.1007/s10456-017-9552-y
Socinski, M. A. et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
pubmed: 29863955
doi: 10.1056/NEJMoa1716948
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
pubmed: 30779529
doi: 10.1056/NEJMoa1816714
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
pubmed: 30779531
pmcid: 6716603
doi: 10.1056/NEJMoa1816047
Makker, V. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 711–718 (2019).
pubmed: 30922731
doi: 10.1016/S1470-2045(19)30020-8
Finn, R. S. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N. Engl. J. Med. 382, 1894–1905 (2020).
pubmed: 32402160
doi: 10.1056/NEJMoa1915745
Chen, D. S. & Hurwitz, H. Combinations of bevacizumab with cancer immunotherapy. Cancer J. 24, 193–204 (2018).
pubmed: 30119083
doi: 10.1097/PPO.0000000000000327
Pober, J. S. & Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nat. Rev. Immunol. 7, 803–815 (2007).
pubmed: 17893694
doi: 10.1038/nri2171
Vestweber, D. How leukocytes cross the vascular endothelium. Nat. Rev. Immunol. 15, 692–704 (2015).
pubmed: 26471775
doi: 10.1038/nri3908
von Andrian, U. H. & Mackay, C. R. T-cell function and migration — two sides of the same coin. N. Engl. J. Med. 343, 1020–1034 (2000).
doi: 10.1056/NEJM200010053431407
Bevilacqua, M. P. Endothelial-leukcoyte adhesion molecules. Annu. Rev. Immuonol. 11, 767–804 (1993).
doi: 10.1146/annurev.iy.11.040193.004003
Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76, 301–314 (1994).
pubmed: 7507411
doi: 10.1016/0092-8674(94)90337-9
Klein, D. The tumor vascular endothelium as decision maker in cancer therapy. Front. Oncol. 8, 367 (2018).
pubmed: 30250827
pmcid: 6139307
doi: 10.3389/fonc.2018.00367
Kuzu, I. et al. Heterogeneity of vascular endothelial cells with relevance to diagnosis of vascular tumours. J. Clin. Pathol. 45, 143–148 (1992).
pubmed: 1371777
pmcid: 495659
doi: 10.1136/jcp.45.2.143
Berger, R. et al. Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J. Cutan. Pathol. 20, 399–406 (1993).
pubmed: 7507944
doi: 10.1111/j.1600-0560.1993.tb00661.x
Dewhirst, M. W. & Dewhirst, M. W. Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res. 52, 4265–4268 (1992).
pubmed: 1638539
Shibata, Y. et al. Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4
pubmed: 7520360
Piali, L., Fichtel, A., Terpe, H. J., Imhof, B. A. & Gisler, R. H. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181, 811–816 (1995).
pubmed: 7530765
doi: 10.1084/jem.181.2.811
Fukumura, D. et al. Tumor necrosis factor α-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res. 55, 4824–4829 (1995).
pubmed: 7585514
Schmidt, J. et al. Reduced basal and stimulated leukocyte adherence in tumor endothelium of experimental pancreatic cancer. Int. J. Gastrointest. Cancer 26, 173–180 (1999).
doi: 10.1385/IJGC:26:3:173
Tromp, S. C. et al. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int. Immunol. 12, 671–676 (2000).
pubmed: 10784613
doi: 10.1093/intimm/12.5.671
Bouma-ter Steege, J. C. et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin. Cancer Res. 10, 7171–7178 (2004).
pubmed: 15534089
doi: 10.1158/1078-0432.CCR-04-0742
Flati, V. et al. Endothelial cell anergy is mediated by bFGF through the sustained activation of p38-MAPK and NF-κB inhibition. Int. J. Immunopathol. Pharmacol. 19, 761–773 (2006).
pubmed: 17166398
doi: 10.1177/039463200601900406
Hellebrekers, D. M. E. I. et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 66, 10770–10777 (2006).
pubmed: 17108113
doi: 10.1158/0008-5472.CAN-06-1609
Kubes, P., Suzuki, M. & Granger, D. N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 88, 4651–4655 (1991).
pubmed: 1675786
pmcid: 51723
doi: 10.1073/pnas.88.11.4651
De Caterina, R. et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J. Clin. Invest. 96, 60–68 (1995).
pubmed: 7542286
pmcid: 185173
doi: 10.1172/JCI118074
Bouzin, C., Brouet, A., De Vriese, J., DeWever, J. & Feron, O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J. Immunol. 178, 1505–1511 (2007).
pubmed: 17237399
doi: 10.4049/jimmunol.178.3.1505
Buckanovich, R. J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14, 28–36 (2008).
pubmed: 18157142
doi: 10.1038/nm1699
Melder, R. J. et al. During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium. Nat. Med. 2, 992–997 (1996).
pubmed: 8782456
doi: 10.1038/nm0996-992
Kevil, C. G. et al. Intercellular adhesion molecule-1 (ICAM-1) regulates endothelial cell motility through a nitric oxide-dependent pathway. J. Biol. Chem. 279, 19230–19238 (2004).
pubmed: 14985356
doi: 10.1074/jbc.M312025200
Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765–772 (1996).
pubmed: 8671665
doi: 10.1093/intimm/8.5.765
Blackburn, S. D. et al. Coregulation of CD8
pubmed: 19043418
doi: 10.1038/ni.1679
Baitsch, L. et al. Exhaustion of tumor-specific CD8
pubmed: 21555851
pmcid: 3104769
doi: 10.1172/JCI46102
Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).
pubmed: 11015443
pmcid: 2193311
doi: 10.1084/jem.192.7.1027
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704 (2008).
pubmed: 18173375
doi: 10.1146/annurev.immunol.26.021607.090331
Nussbaum, C. et al. Neutrophil and endothelial adhesive function during human fetal ontogeny. J. Leukoc. Biol. 93, 175–184 (2013).
pubmed: 23233729
pmcid: 4050519
doi: 10.1189/jlb.0912468
Larson, B. J., Longaker, M. T. & Lorenz, H. P. Scarless fetal wound healing: a basic science review. Plast. Reconstr. Surg. 126, 1172–1180 (2010).
pubmed: 20885241
pmcid: 4229131
doi: 10.1097/PRS.0b013e3181eae781
Lo, D. D., Zimmermann, A. S., Nauta, A., Longaker, M. T. & Lorenz, H. P. Scarless fetal skin wound healing update. Birth Defects Res. C. Embryo Today Rev. 96, 237–247 (2012).
doi: 10.1002/bdrc.21018
Reinke, J. M. & Sorg, H. Wound repair and regeneration. Eur. Surg. Res. 49, 35–43 (2012).
pubmed: 22797712
doi: 10.1159/000339613
Demir, R., Seval, Y. & Huppertz, B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem. 109, 257–265 (2007).
pubmed: 17574656
doi: 10.1016/j.acthis.2007.02.008
Shechter, R., London, A. & Schwartz, M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat. Rev. Immunol. 13, 206–218 (2013).
pubmed: 23435332
doi: 10.1038/nri3391
Hua, Y. & Bergers, G. Tumors vs. chronic wounds: an immune cell’s perspective. Front. Immunol. 10, 2178 (2019).
pubmed: 31572387
pmcid: 6751250
doi: 10.3389/fimmu.2019.02178
Landén, N. X., Li, D. & Ståhle, M. Transition from inflammation to proliferation: a critical step during wound healing. Cell. Mol. Life Sci. 73, 3861–3885 (2016).
pubmed: 27180275
pmcid: 5021733
doi: 10.1007/s00018-016-2268-0
De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474 (2017).
pubmed: 28706266
doi: 10.1038/nrc.2017.51
Missiaen, R., Mazzone, M. & Bergers, G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin. Cancer Biol. 52, 107–116 (2018).
pubmed: 29935312
pmcid: 6548870
doi: 10.1016/j.semcancer.2018.06.002
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467–477 (2008).
pubmed: 18500231
doi: 10.1038/nri2326
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
pubmed: 29567705
pmcid: 7391259
doi: 10.1126/science.aar4060
Flier, J. S., Underhill, L. H. & Dvorak, H. F. Tumors: wounds that do not heal. N. Engl. J. Med. 315, 1650–1659 (1986).
doi: 10.1056/NEJM198612253152606
Topalian, S. L. et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
pubmed: 22658127
pmcid: 3544539
doi: 10.1056/NEJMoa1200690
Gettinger, S. N. et al. Overall survival and long-term safety of nivolumab (Anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer. J. Clin. Oncol. 33, 2004–2012 (2015).
pubmed: 25897158
pmcid: 4672027
doi: 10.1200/JCO.2014.58.3708
Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014).
pubmed: 24590637
pmcid: 4811023
doi: 10.1200/JCO.2013.53.0105
Griffioen, A. W. et al. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy. Int. J. Cancer 80, 315–319 (1999).
pubmed: 9935216
doi: 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L
Tabruyn, S. P. et al. The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-κB activation. Mol. Endocrinol. 21, 1422–1429 (2007).
pubmed: 17405903
doi: 10.1210/me.2007-0021
Zhang, H. & Issekutz, A. C. Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor. Am. J. Pathol. 160, 2219–2230 (2002).
pubmed: 12057924
pmcid: 1850845
doi: 10.1016/S0002-9440(10)61169-8
Dirkx, A. E. M. et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 20, 621–630 (2006).
pubmed: 16581970
doi: 10.1096/fj.05-4493com
Dings, R. P. M. et al. Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer. Clin. Cancer Res. 17, 3134–3145 (2011).
pubmed: 21252159
pmcid: 4242153
doi: 10.1158/1078-0432.CCR-10-2443
Thijssen, V. L., Heusschen, R., Caers, J. & Griffioen, A. W. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim. Biophys. Acta Rev. Cancer 1855, 235–247 (2015).
doi: 10.1016/j.bbcan.2015.03.003
Thijssen, V. L. J. L. et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl Acad. Sci. USA 103, 15975–15980 (2006).
pubmed: 17043243
pmcid: 1635112
doi: 10.1073/pnas.0603883103
Rabinovich, G. A. & Toscano, M. A. Turning ‘sweet’ on immunity: galectin–glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9, 338–352 (2009).
pubmed: 19365409
doi: 10.1038/nri2536
Perillo, N. L., Pace, K. E., Seilhamer, J. J. & Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 378, 736–739 (1995).
pubmed: 7501023
doi: 10.1038/378736a0
Chung, C. D., Patel, V. P., Moran, M., Lewis, L. A. & Miceli, M. C. Galectin-1 induces partial TCR ζ-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol. 165, 3722–3729 (2000).
pubmed: 11034377
doi: 10.4049/jimmunol.165.7.3722
Blaser, C. et al. β-Galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur. J. Immunol. 28, 2311–2319 (1998).
pubmed: 9710209
doi: 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G
Matarrese, P. et al. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem. 280, 6969–6985 (2005).
pubmed: 15556941
doi: 10.1074/jbc.M409752200
Clausse, N., Van Den Brûle, F., Waltregny, D., Garnier, F. & Castronovo, V. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 3, 317–325 (1999).
pubmed: 14517411
doi: 10.1023/A:1026584523789
He, J. & Baum, L. G. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab. Invest. 86, 578–590 (2006).
pubmed: 16607379
doi: 10.1038/labinvest.3700420
Norling, L. V., Sampaio, A. L. F., Cooper, D. & Perretti, M. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 22, 682–690 (2008).
pubmed: 17965266
doi: 10.1096/fj.07-9268com
La, M. et al. A novel biological activity for galectin-1. Am. J. Pathol. 163, 1505–1515 (2003).
pubmed: 14507657
pmcid: 1868297
doi: 10.1016/S0002-9440(10)63507-9
Rubinstein, N. et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection. Cancer Cell 5, 241–251 (2004).
pubmed: 15050916
doi: 10.1016/S1535-6108(04)00024-8
Dalotto-Moreno, T. et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res. 73, 1107–1117 (2013).
pubmed: 23204230
doi: 10.1158/0008-5472.CAN-12-2418
Nambiar, D. K. et al. Galectin-1–driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J. Clin. Invest. 129, 5553–5567 (2019).
pubmed: 31710313
pmcid: 6877340
doi: 10.1172/JCI129025
Motz, G. T. et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20, 607–615 (2014).
pubmed: 24793239
pmcid: 4060245
doi: 10.1038/nm.3541
Huang, X. et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J. Exp. Med. 207, 505–520 (2010).
pubmed: 20176801
pmcid: 2839144
doi: 10.1084/jem.20090397
Rodig, N. et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8
pubmed: 14579280
doi: 10.1002/eji.200324270
Mazanet, M. M. & Hughes, C. C. W. B7-H1 Is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169, 3581–3588 (2002).
pubmed: 12244148
doi: 10.4049/jimmunol.169.7.3581
Grabie, N. et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8
pubmed: 17938288
doi: 10.1161/CIRCULATIONAHA.107.709360
Chen, W.-J. et al. Human umbilical vein endothelial cells promote the inhibitory activation of CD4
pubmed: 26615520
doi: 10.1016/j.atherosclerosis.2015.11.002
Kamada, T. et al. PD-1
pubmed: 31028147
pmcid: 6525547
doi: 10.1073/pnas.1822001116
Kumagai, S. et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat. Immunol. 21, 1346–1358 (2020).
pubmed: 32868929
doi: 10.1038/s41590-020-0769-3
Liu, S. et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 11, 309 (2020).
pubmed: 32366856
pmcid: 7198575
doi: 10.1038/s41419-020-2511-3
Allen, E. et al. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl Med. 9, eaak9679 (2017).
pubmed: 28404866
pmcid: 5554432
doi: 10.1126/scitranslmed.aak9679
Shigeta, K. et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology 71, 1247–1261 (2020).
pubmed: 31378984
doi: 10.1002/hep.30889
Schmittnaegel, M. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl Med. 9, eaak9670 (2017).
pubmed: 28404865
doi: 10.1126/scitranslmed.aak9670
Riesenberg, R. et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 13, 6993–7002 (2007).
pubmed: 18056175
doi: 10.1158/1078-0432.CCR-07-0942
Blaschitz, A. et al. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS ONE 6, e21774 (2011).
pubmed: 21755000
pmcid: 3130744
doi: 10.1371/journal.pone.0021774
Shetty, S. et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J. Immunol. 186, 4147–4155 (2011).
pubmed: 21368224
doi: 10.4049/jimmunol.1002961
Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592–603 (2008).
pubmed: 18650835
pmcid: 2874834
doi: 10.1038/nrc2442
Ebos, J. M. L. & Kerbel, R. S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210–221 (2011).
pubmed: 21364524
pmcid: 4540336
doi: 10.1038/nrclinonc.2011.21
Bajou, K. et al. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat. Med. 20, 741–747 (2014).
pubmed: 24929950
doi: 10.1038/nm.3552
Griffioen, A. W. et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 354, 233 (2001).
pubmed: 11171099
pmcid: 1221648
doi: 10.1042/bj3540233
Kim, M. S. et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7, 437–443 (2001).
pubmed: 11283670
doi: 10.1038/86507
Hellebrekers, D. M. E. I. et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol. Cancer Ther. 5, 467–475 (2006).
pubmed: 16505122
doi: 10.1158/1535-7163.MCT-05-0417
Huang, Y. et al. Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors. Nat. Commun. 11, 622 (2020).
pubmed: 32001695
pmcid: 6992734
doi: 10.1038/s41467-020-14425-7
Weishaupt, C. et al. Activation of human vascular endothelium in melanoma metastases induces ICAM-1 and E-selectin expression and results in increased infiltration with effector lymphocytes. Exp. Dermatol. 28, 1258–1269 (2019).
pubmed: 31444891
doi: 10.1111/exd.14023
Calcinotto, A. et al. Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol. 188, 2687–2694 (2012).
pubmed: 22323546
doi: 10.4049/jimmunol.1101877
Fisher, D. T. et al. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121, 3846–3859 (2011).
pubmed: 21926464
pmcid: 3195455
doi: 10.1172/JCI44952
Gabrilovich, D. I., Ishida, T., Nadaf, S., Ohm, J. E. & Carbone, D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963–2970 (1999).
pubmed: 10537366
Ishida, T., Oyama, T., Carbone, D. P. & Gabrilovich, D. I. Defective function of langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J. Immunol. 161, 4842–4851 (1998).
pubmed: 9794417
doi: 10.4049/jimmunol.161.9.4842
Manzoni, M. et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 79, 187–196 (2010).
pubmed: 21358206
doi: 10.1159/000320609
Martino, E. et al. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2, 16025 (2016).
pubmed: 27752361
pmcid: 5045963
doi: 10.1038/cddiscovery.2016.25
Ozao-Choy, J. et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 69, 2514–2522 (2009).
pubmed: 19276342
pmcid: 4370269
doi: 10.1158/0008-5472.CAN-08-4709
Finke, J. H. et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14, 6674–6682 (2008).
pubmed: 18927310
doi: 10.1158/1078-0432.CCR-07-5212
Adotevi, O. et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33, 991–998 (2010).
pubmed: 20948437
doi: 10.1097/CJI.0b013e3181f4c208
Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148–2157 (2009).
pubmed: 19276286
doi: 10.1158/1078-0432.CCR-08-1332
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
pubmed: 15637262
doi: 10.1126/science.1104819
Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 10, 417–427 (2011).
pubmed: 21629292
doi: 10.1038/nrd3455
Weiss, A. et al. Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci. Rep. 5, 8990 (2015).
pubmed: 25758612
pmcid: 4355632
doi: 10.1038/srep08990
Shrimali, R. K. et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70, 6171–6180 (2010).
pubmed: 20631075
pmcid: 2912959
doi: 10.1158/0008-5472.CAN-10-0153
Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561–17566 (2012).
pubmed: 23045683
pmcid: 3491458
doi: 10.1073/pnas.1215397109
Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414 (2008).
pubmed: 18418378
doi: 10.1038/nature06868
Mazzieri, R. et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19, 512–526 (2011).
pubmed: 21481792
doi: 10.1016/j.ccr.2011.02.005
Di Tacchio, M. et al. Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, angiopoietin-2, and VEGF. Cancer Immunol. Res. 7, 1910–1927 (2019).
pubmed: 31597643
doi: 10.1158/2326-6066.CIR-18-0865
Johansson-Percival, A. et al. Intratumoral LIGHT restores pericyte contractile properties and vessel integrity. Cell Rep. 13, 2687–2698 (2015).
pubmed: 26711337
doi: 10.1016/j.celrep.2015.12.004
He, B. et al. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J. Pathol. 245, 209–221 (2018).
pubmed: 29603739
pmcid: 6737176
doi: 10.1002/path.5080
Johansson-Percival, A. et al. De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. Nat. Immunol. 18, 1207–1217 (2017).
pubmed: 28892469
doi: 10.1038/ni.3836
Otterdal, K. et al. Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. Blood 108, 928–935 (2006).
pubmed: 16861346
doi: 10.1182/blood-2005-09-010629
Girard, J.-P. & Springer, T. A. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol. Today 16, 449–457 (1995).
pubmed: 7546210
doi: 10.1016/0167-5699(95)80023-9
Milutinovic, S., Abe, J., Godkin, A., Stein, J. V. & Gallimore, A. The dual role of high endothelial venules in cancer progression versus immunity. Trends Cancer 7, 214–225 (2021).
pubmed: 33132107
doi: 10.1016/j.trecan.2020.10.001
Sawa, Y. et al. Immunohistochemical study on leukocyte adhesion molecules expressed on lymphatic endothelium. Microvasc. Res. 57, 292–297 (1999).
pubmed: 10329255
doi: 10.1006/mvre.1998.2137
Guislain, A. et al. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol. Immunother. 64, 1241–1250 (2015).
pubmed: 26105626
doi: 10.1007/s00262-015-1735-z
Ragusa, S. et al. Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice. J. Clin. Invest. 130, 1199–1216 (2020).
pubmed: 32015230
pmcid: 7269598
doi: 10.1172/JCI129558
Li, H. et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J. Immunother. 43, 16–28 (2020).
pubmed: 31574023
doi: 10.1097/CJI.0000000000000301
Bocca, P. et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model. Oncoimmunology 7, e1378843 (2018).
doi: 10.1080/2162402X.2017.1378843
Manning, E. A. et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 13, 3951–3959 (2007).
pubmed: 17606729
doi: 10.1158/1078-0432.CCR-07-0374
Yasuda, S. et al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Clin. Exp. Immunol. 172, 500–506 (2013).
pubmed: 23600839
pmcid: 3646450
doi: 10.1111/cei.12069
Leenders, W. P. J., Küsters, B. & de Waal, R. M. W. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 9, 83–87 (2002).
pubmed: 12200959
doi: 10.1080/10623320212006
Maniotis, A. J. et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739–752 (1999).
pubmed: 10487832
pmcid: 1866899
doi: 10.1016/S0002-9440(10)65173-5
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S. & Reynolds, A. R. Vessel co-option in cancer. Nat. Rev. Clin. Oncol. 16, 469–493 (2019).
pubmed: 30816337
doi: 10.1038/s41571-019-0181-9
Bridgeman, V. L. et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 241, 362–374 (2017).
pubmed: 27859259
doi: 10.1002/path.4845
Hu, J. et al. Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene 24, 1212–1219 (2005).
pubmed: 15592519
doi: 10.1038/sj.onc.1208242
Van den Eynden, G. G. et al. The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clin. Exp. Metastasis 29, 541–549 (2012).
pubmed: 22476470
doi: 10.1007/s10585-012-9469-1
Van Dam, P. J. et al. Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. Semin. Cancer Biol. 52, 86–93 (2018).
pubmed: 29355613
doi: 10.1016/j.semcancer.2018.01.009
Hendrix, M. J. C., Seftor, E. A., Hess, A. R. & Seftor, R. E. B. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat. Rev. Cancer 3, 411–421 (2003).
pubmed: 12778131
doi: 10.1038/nrc1092
Paulis, Y. W. J., Soetekouw, P. M. M. B., Verheul, H. M. W., Tjan-Heijnen, V. C. G. & Griffioen, A. W. Signalling pathways in vasculogenic mimicry. Biochim. Biophys. Acta Rev. Cancer 1806, 18–28 (2010).
doi: 10.1016/j.bbcan.2010.01.001
van der Schaft, D. W. J. et al. Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res. 65, 11520–11528 (2005).
pubmed: 16357161
doi: 10.1158/0008-5472.CAN-05-2468
van der Schaft, D. W. J. et al. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J. Natl Cancer Inst. 96, 1473–1477 (2004).
pubmed: 15467037
doi: 10.1093/jnci/djh267
Vartanian, A. et al. Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents. Melanoma Res. 27, 8–16 (2017).
pubmed: 27776018
doi: 10.1097/CMR.0000000000000308
van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J. M., Thijssen, V. L. & Griffioen, A. W. The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol. Rev. 67, 441–461 (2015).
pubmed: 25769965
doi: 10.1124/pr.114.010215
Makker, V. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J. Clin. Oncol. 38, 2981–2992 (2020).
pubmed: 32167863
pmcid: 7479759
doi: 10.1200/JCO.19.02627
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nat. Med. 26, 1733–1741 (2020).
pubmed: 32895571
doi: 10.1038/s41591-020-1044-8
pmcid: 8493486
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).
pubmed: 29867230
pmcid: 6721896
doi: 10.1038/s41591-018-0053-3
Giraldo, N. A. et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin. Cancer Res. 23, 4416–4428 (2017).
pubmed: 28213366
doi: 10.1158/1078-0432.CCR-16-2848
Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909–918 (2020).
pubmed: 32472114
pmcid: 7499153
doi: 10.1038/s41591-020-0839-y
Lan, C. et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J. Clin. Oncol. 38, 4095–4106 (2020).
pubmed: 33052760
doi: 10.1200/JCO.20.01920
pmcid: 7768345
Jaini, R., Rayman, P., Cohen, P. A., Finke, J. H. & Tuohy, V. K. Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. Int. J. Cancer 134, 1695–1705 (2014).
pubmed: 24105638
doi: 10.1002/ijc.28488
Liu, X.-D. et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol. Res. 3, 1017–1029 (2015).
pubmed: 26014097
pmcid: 4561186
doi: 10.1158/2326-6066.CIR-14-0244
Taube, J. M. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl Med. 4, 127ra37 (2012).
pubmed: 22461641
pmcid: 3568523
doi: 10.1126/scitranslmed.3003689
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L. & Bianco, R. Combining immune checkpoint inhibitors with anti-angiogenic agents. J. Clin. Med. 9, 675 (2020).
pmcid: 7141336
doi: 10.3390/jcm9030675
Tian, L. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544, 250–254 (2017).
pubmed: 28371798
pmcid: 5788037
doi: 10.1038/nature21724
Wentink, M. Q. et al. Vaccination approach to anti-angiogenic treatment of cancer. Biochim. Biophys. Acta Rev. Cancer 1855, 155–171 (2015).
doi: 10.1016/j.bbcan.2015.01.005
Jackson, H. J., Rafiq, S. & Brentjens, R. J. Driving CAR T-cells forward. Nat. Rev. Clin. Oncol. 13, 370–383 (2016).
pubmed: 27000958
pmcid: 5529102
doi: 10.1038/nrclinonc.2016.36
Kakarla, S. & Gottschalk, S. CAR T cells for solid tumors. Cancer J. 20, 151–155 (2014).
pubmed: 24667962
pmcid: 4050065
doi: 10.1097/PPO.0000000000000032
Akbari, P., Huijbers, E. J. M., Themeli, M., Griffioen, A. W. & van Beijnum, J. R. The tumor vasculature an attractive CAR T cell target in solid tumors. Angiogenesis 22, 473–475 (2019).
pubmed: 31628559
pmcid: 6864117
doi: 10.1007/s10456-019-09687-9
Niethammer, A. G. et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8, 1369–1375 (2002).
pubmed: 12415261
doi: 10.1038/nm1202-794
Facciponte, J. G. et al. Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature. J. Clin. Invest. 124, 1497–1511 (2014).
pubmed: 24642465
pmcid: 3973096
doi: 10.1172/JCI67382
Wentink, M. Q. et al. Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity. Proc. Natl Acad. Sci. USA 113, 12532–12537 (2016).
pubmed: 27791128
pmcid: 5098619
doi: 10.1073/pnas.1610258113
Huijbers, E. J. M. et al. Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J. 24, 4535–4544 (2010).
pubmed: 20634349
doi: 10.1096/fj.10-163022
Zhuang, X. et al. Robo4 vaccines induce antibodies that retard tumor growth. Angiogenesis 18, 83–95 (2015).
pubmed: 25348086
doi: 10.1007/s10456-014-9448-z
Huijbers, E. J. M. et al. Targeting tumor vascular CD99 inhibits tumor growth. Front. Immunol. 10, 651 (2019).
pubmed: 31001265
pmcid: 6455290
doi: 10.3389/fimmu.2019.00651
Scalia, R., Booth, G. & Lefer, D. J. Vascular endothelial growth factor attenuates leukocyte–endothelium interaction during acute endothelial dysfunction: essential role of endothelium-derived nitric oxide. FASEB J. 13, 1039–1046 (1999).
pubmed: 10336886
doi: 10.1096/fasebj.13.9.1039
Minshall, R. D., Sessa, W. C., Stan, R. V., Anderson, R. G. W. & Malik, A. B. Caveolin regulation of endothelial function. Am. J. Physiol. Cell. Mol. Physiol. 285, L1179–L1183 (2003).
doi: 10.1152/ajplung.00242.2003
Weiss, A. et al. Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer. Angiogenesis 18, 233–244 (2015).
pubmed: 25824484
pmcid: 4473022
doi: 10.1007/s10456-015-9462-9
Nowak-Sliwinska, P. et al. Optimization of drug combinations using feedback system control. Nat. Protoc. 11, 302–315 (2016).
pubmed: 26766116
doi: 10.1038/nprot.2016.017
Ho, D. Artificial intelligence in cancer therapy. Science 367, 982–983 (2020).
pubmed: 32108102
doi: 10.1126/science.aaz3023
Sicklick, J. K. et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat. Med. 25, 744–750 (2019).
pubmed: 31011206
pmcid: 6553618
doi: 10.1038/s41591-019-0407-5
Mougel, A., Terme, M. & Tanchot, C. Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade. Front. Immunol. 10, 467 (2019).
pubmed: 30923527
pmcid: 6426771
doi: 10.3389/fimmu.2019.00467
Argentiero, A. et al. Anti-angiogenesis and immunotherapy: novel paradigms to envision tailored approaches in renal cell-carcinoma. J. Clin. Med. 9, 1594 (2020).
pmcid: 7291047
doi: 10.3390/jcm9051594
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725–741 (2020).
pubmed: 32760014
doi: 10.1038/s41571-020-0413-z
Formenti, S. C. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 24, 1845–1851 (2018).
pubmed: 30397353
pmcid: 6286242
doi: 10.1038/s41591-018-0232-2